Literature DB >> 25702136

The Role of Matrix Metalloproteinase 3 and 9 in the Pathogenesis of Acute Neuroinflammation. Implications for Disease Modifying Therapy.

Srdjan Ljubisavljevic1,2, I Stojanovic3, J Basic3, S Vojinovic4, D Stojanov5, G Djordjevic4, D Pavlovic3.   

Abstract

Matrix metalloproteinases (MMPs) are proteolytic enzymes that are involved in a variety of physiological and pathological processes, including those in CNS. In this study, plasma values of MMP-3 and MMP-9 have been compared in clinically isolated syndrome (CIS) and relapsing-remitting multiple sclerosis (RRMS) patients during their acute attacks, in relation to the biological activity of disease. Therefore, we compared the MMPs plasma values regarding Expanded Disability Status Scale (EDSS), progression index of disease (PID), acute brain lesion volume seen on magnetic resonance imaging (MRI) and index of blood-brain barrier (BBB) permeability destruction. The obtained results demonstrated higher plasma values of MMPs in both study groups than control values (p < 0.05). No statistical significances have been detected comparing the obtained values of both enzymes between CIS and RRMS group (p > 0.05). In both CIS and RRMS groups, the patients with higher EDSS showed higher MMPs plasma values (p < 0.05). The MMPs values were also significantly higher in both study patients with higher total number comparing to those with lower number of MRI brain lesion (p < 0.05) (beyond MMP-3 in RRMS). All obtained correlations, between MMPs and EDSS, PID, volume of MRI Gd-enhancement brain lesions, and index of BBB permeability, were positive (p < 0.05.) This study demonstrates alterations of both tested MMPs with closed correlation with the disease biological activity. Although MMPs are being implicated in the pathogenesis of acute neuroinflammation, the MMPs modulation might be useful in the future design of disease modifying therapy with the specific target profile.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25702136     DOI: 10.1007/s12031-015-0521-x

Source DB:  PubMed          Journal:  J Mol Neurosci        ISSN: 0895-8696            Impact factor:   3.444


  31 in total

Review 1.  Matrix metalloproteinases and neuroinflammation in multiple sclerosis.

Authors:  Gary A Rosenberg
Journal:  Neuroscientist       Date:  2002-12       Impact factor: 7.519

Review 2.  Mechanisms, challenges and opportunities in stroke.

Authors:  Eng H Lo; Turgay Dalkara; Michael A Moskowitz
Journal:  Nat Rev Neurosci       Date:  2003-05       Impact factor: 34.870

3.  Alterations in serum MMP-8, MMP-9, IL-12p40 and IL-23 in multiple sclerosis patients treated with interferon-beta1b.

Authors:  J S Alexander; M K Harris; S R Wells; G Mills; K Chalamidas; V C Ganta; J McGee; M H Jennings; E Gonzalez-Toledo; A Minagar
Journal:  Mult Scler       Date:  2010-07       Impact factor: 6.312

4.  An elevated matrix metalloproteinase (MMP) in an animal model of multiple sclerosis is protective by affecting Th1/Th2 polarization.

Authors:  Andrew Weaver; Angelika Goncalves da Silva; Robert K Nuttall; Dylan R Edwards; Steven D Shapiro; Serge Rivest; V Wee Yong
Journal:  FASEB J       Date:  2005-08-04       Impact factor: 5.191

5.  Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis.

Authors:  F D Lublin; S C Reingold
Journal:  Neurology       Date:  1996-04       Impact factor: 9.910

6.  Serum matrix metalloproteinase-3 levels correlate with disease activity in relapsing-remitting multiple sclerosis.

Authors:  T Kanesaka; M Mori; T Hattori; T Oki; S Kuwabara
Journal:  J Neurol Neurosurg Psychiatry       Date:  2006-02       Impact factor: 10.154

7.  Matrix metalloproteinase-9 facilitates remyelination in part by processing the inhibitory NG2 proteoglycan.

Authors:  Peter H Larsen; Jennifer E Wells; William B Stallcup; Ghislain Opdenakker; V Wee Yong
Journal:  J Neurosci       Date:  2003-12-03       Impact factor: 6.167

8.  IFNbeta lowers MMP-9/TIMP-1 ratio, which predicts new enhancing lesions in patients with SPMS.

Authors:  E Waubant; D Goodkin; A Bostrom; P Bacchetti; J Hietpas; R Lindberg; D Leppert
Journal:  Neurology       Date:  2003-01-14       Impact factor: 9.910

9.  Effective treatment of models of multiple sclerosis by matrix metalloproteinase inhibitors.

Authors:  W Liedtke; B Cannella; R J Mazzaccaro; J M Clements; K M Miller; K W Wucherpfennig; A J Gearing; C S Raine
Journal:  Ann Neurol       Date:  1998-07       Impact factor: 10.422

10.  Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria.

Authors:  Chris H Polman; Stephen C Reingold; Brenda Banwell; Michel Clanet; Jeffrey A Cohen; Massimo Filippi; Kazuo Fujihara; Eva Havrdova; Michael Hutchinson; Ludwig Kappos; Fred D Lublin; Xavier Montalban; Paul O'Connor; Magnhild Sandberg-Wollheim; Alan J Thompson; Emmanuelle Waubant; Brian Weinshenker; Jerry S Wolinsky
Journal:  Ann Neurol       Date:  2011-02       Impact factor: 10.422

View more
  10 in total

1.  Minocycline treatment in clinically isolated syndrome and serum NfL, GFAP, and metalloproteinase levels.

Authors:  Carlos Camara-Lemarroy; Luanne Metz; Jens Kuhle; David Leppert; Eline Willemse; David Kb Li; Anthony Traboulsee; Jamie Greenfield; Graziela Cerchiaro; Claudia Silva; V Wee Yong
Journal:  Mult Scler       Date:  2022-07-18       Impact factor: 5.855

2.  MMP-3 Deficiency Alleviates Endotoxin-Induced Acute Inflammation in the Posterior Eye Segment.

Authors:  Inge Van Hove; Evy Lefevere; Lies De Groef; Jurgen Sergeys; Manuel Salinas-Navarro; Claude Libert; Roosmarijn Vandenbroucke; Lieve Moons
Journal:  Int J Mol Sci       Date:  2016-11-01       Impact factor: 5.923

3.  Matrix metalloproteinase-9 activity and a downregulated Hedgehog pathway impair blood-brain barrier function in an in vitro model of CNS tuberculosis.

Authors:  Sara Brilha; Catherine W M Ong; Babette Weksler; Nacho Romero; Pierre-Olivier Couraud; Jon S Friedland
Journal:  Sci Rep       Date:  2017-11-22       Impact factor: 4.379

4.  Autologous Bone Marrow Transplantation in Multiple Sclerosis: Biomarker Relevance for Patient Recruitment and Follow up.

Authors:  Ana C Londoño; Carlos A Mora
Journal:  J Clin Cell Immunol       Date:  2016-09-20

5.  Dynamic changes of MMP-9 plasma levels correlate with JCV reactivation and immune activation in natalizumab-treated multiple sclerosis patients.

Authors:  Marco Iannetta; Maria Antonella Zingaropoli; Tiziana Latronico; Ilaria Pati; Simona Pontecorvo; Carla Prezioso; Valeria Pietropaolo; Antonio Cortese; Marco Frontoni; Claudia D'Agostino; Ada Francia; Vincenzo Vullo; Claudio Maria Mastroianni; Grazia Maria Liuzzi; Maria Rosa Ciardi
Journal:  Sci Rep       Date:  2019-01-22       Impact factor: 4.379

Review 6.  Matrix metalloproteinases: Expression, regulation and role in the immunopathology of tuberculosis.

Authors:  Naveed Sabir; Tariq Hussain; Mazhar Hussain Mangi; Deming Zhao; Xiangmei Zhou
Journal:  Cell Prolif       Date:  2019-06-14       Impact factor: 6.831

7.  Dimethyl itaconate, an itaconate derivative, exhibits immunomodulatory effects on neuroinflammation in experimental autoimmune encephalomyelitis.

Authors:  Ping-Chang Kuo; Wen-Tsan Weng; Barbara A Scofield; Hallel C Paraiso; Dennis A Brown; Pei-Yu Wang; I-Chen Yu; Jui-Hung Yen
Journal:  J Neuroinflammation       Date:  2020-04-29       Impact factor: 8.322

8.  Neuroprotective effects of four different fluids on cerebral ischaemia/reperfusion injury in rats through stabilization of the blood-brain barrier.

Authors:  Reai Shan; Hongyan Zhou; Xinfang Liu; Guangjun Su; Guangsen Liu; Xiaoli Zhang; Cong Sun; Zining Yu; Lifang Zhan; Zhihua Huang
Journal:  Eur J Neurosci       Date:  2021-07-26       Impact factor: 3.698

Review 9.  Albumin and multiple sclerosis.

Authors:  Steven M LeVine
Journal:  BMC Neurol       Date:  2016-04-12       Impact factor: 2.474

10.  Critical role of matrix metallopeptidase 9 in postoperative cognitive dysfunction and age-dependent cognitive decline.

Authors:  Jiangjiang Bi; Weiran Shan; Ailin Luo; Zhiyi Zuo
Journal:  Oncotarget       Date:  2017-02-20
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.